Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for your continued patience. Your meeting will begin shortly. If you do need assistance at any time today, please press star zero, and a member of our team will be happy to help you. ¶¶ Thank you. ¶¶ ¦ ¦ ¦ ¶¶ © transcript Emily Beynon Ladies and gentlemen, again, thank you for your continued patience. Your meeting will begin shortly. Again, if you do need any assistance on today's call, please press star zero, and a member of our team will be happy to help you. ¶¶ © transcript Emily Beynon © transcript Emily Beynon ¶¶ Please stand by, your meeting is about to begin. Good day, ladies and gentlemen, and welcome to the Verica Pharmaceuticals first quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's remarks, there will be a question and answer session. As a reminder, this conference is being recorded. I will now turn the call over to our host, Kevin Gardner of LifeSite Advisors. You may begin your conference. Thank you, operator. Hello, everyone, and welcome to Verica Pharmaceutical's first quarter 2026 corporate update conference call. With me on the line this evening are Jason Rieger, President and Chief Executive Officer, Noah Rosenberg, Chief Medical Officer, John Kirby, Interim Chief Financial Officer, David Zawitz, Chief Operating Officer, and Chris Chapman, Chief Commercial Officer. As a reminder, during today's call, management will make forward-looking statements. These forward-looking statements are based on the company's current expectations and involve inherent risks and uncertainties. Verica's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. Please see Verica's SEC filings for important ris...